CRIS Current Research Information System

BRANDI, GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.118
EU - Europa 8.124
AS - Asia 3.817
AF - Africa 518
SA - Sud America 40
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 8
Totale 23.634
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.077
GB - Regno Unito 2.173
SE - Svezia 1.211
VN - Vietnam 1.206
IT - Italia 1.152
DE - Germania 1.059
CN - Cina 1.035
SG - Singapore 823
IE - Irlanda 549
IN - India 520
CH - Svizzera 454
UA - Ucraina 320
RU - Federazione Russa 310
FR - Francia 286
TG - Togo 178
ZA - Sudafrica 177
EE - Estonia 159
FI - Finlandia 127
JO - Giordania 96
BG - Bulgaria 86
CI - Costa d'Avorio 80
BE - Belgio 47
NG - Nigeria 45
AT - Austria 39
CA - Canada 39
GR - Grecia 31
SC - Seychelles 25
IR - Iran 22
JP - Giappone 22
NL - Olanda 21
HR - Croazia 20
PL - Polonia 18
BR - Brasile 16
CL - Cile 16
RO - Romania 14
KR - Corea 13
ES - Italia 12
TR - Turchia 12
LB - Libano 10
HK - Hong Kong 9
UZ - Uzbekistan 9
PS - Palestinian Territory 8
CZ - Repubblica Ceca 7
PT - Portogallo 7
A2 - ???statistics.table.value.countryCode.A2??? 6
AU - Australia 6
MY - Malesia 6
TN - Tunisia 5
EC - Ecuador 4
HU - Ungheria 4
ID - Indonesia 4
LT - Lituania 4
PH - Filippine 4
DK - Danimarca 3
DZ - Algeria 3
NZ - Nuova Zelanda 3
SA - Arabia Saudita 3
SK - Slovacchia (Repubblica Slovacca) 3
TW - Taiwan 3
AE - Emirati Arabi Uniti 2
AR - Argentina 2
BD - Bangladesh 2
EG - Egitto 2
EU - Europa 2
GH - Ghana 2
MX - Messico 2
RS - Serbia 2
SI - Slovenia 2
IL - Israele 1
IQ - Iraq 1
KH - Cambogia 1
KW - Kuwait 1
KZ - Kazakistan 1
LK - Sri Lanka 1
MC - Monaco 1
MD - Moldavia 1
MU - Mauritius 1
NO - Norvegia 1
PE - Perù 1
PK - Pakistan 1
SM - San Marino 1
TH - Thailandia 1
VE - Venezuela 1
Totale 23.634
Salva come PNG Salva come JPEG
Città #
Southend 1.998
Chandler 1.329
Fairfield 1.286
Dong Ket 832
Ashburn 784
Singapore 709
Princeton 634
Wilmington 597
Houston 590
Woodbridge 578
Seattle 523
Dublin 499
Bern 438
Cambridge 424
Ann Arbor 369
Bologna 280
Westminster 202
Nanjing 200
Jacksonville 190
Lomé 178
Padova 169
Santa Clara 165
Berlin 149
New York 142
San Diego 119
Helsinki 115
Menlo Park 112
Jinan 103
Medford 99
Amman 96
Saint Petersburg 96
Beijing 94
Redmond 88
Shenyang 84
Sofia 84
Abidjan 80
Hebei 77
Turin 68
Florence 65
Changsha 62
Nanchang 62
Milan 59
Mülheim 57
Jiaxing 47
Boardman 46
Abeokuta 45
Brussels 45
Des Moines 41
Los Angeles 39
Redwood City 37
Dearborn 35
Olalla 34
Tianjin 33
Norwalk 32
Kuban 31
Pune 31
Toronto 31
Zhengzhou 31
Bremen 30
Rome 30
Bühl 29
Hangzhou 29
Vienna 29
Fremont 27
London 25
Mahé 25
Haikou 24
Taizhou 23
Frankfurt am Main 21
Paris 21
Lanzhou 20
Ningbo 20
Chicago 19
Falls Church 19
Mountain View 19
Guangzhou 17
Tokyo 17
Hyderabad 16
Kunming 16
San Francisco 16
Taiyuan 15
Monmouth Junction 14
São Paulo 14
Lappeenranta 12
San Venanzo 12
Hefei 11
Verona 11
Boydton 10
Washington 10
Leawood 9
Moscow 9
Ardabil 8
Catania 8
Council Bluffs 8
Forlì 8
Halhul 8
Lausanne 8
Siena 8
Warsaw 8
Amsterdam 7
Totale 16.133
Salva come PNG Salva come JPEG
Nome #
Asbestos: a hidden player behind the cholangiocarcinoma increase? Findings from a case–control analysis 333
Adjuvant treatment in biliary tract cancer 201
Circadian variations of rectal cell proliferation in patients affected by advanced colorectal cancer. 190
A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma. 188
Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases. 184
Adjuvant chemotherapy for resected colorectal cancer metastases: literature revision and meta-analysis 184
Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations 178
Antiprotease strategy in combination with gemcitabine as a putative novel therapeutic approach for pancreatic cancer treatment 175
219 MiR-21 expression correlates with prognosis in extrahepatic radically resected cholangiocarcinomas treated with gemcitabine-based adjuvant chemotherapy 169
Antiprotease strategy in pancreatic cancer treatment: emergence from a preclinical study. 165
Chemotherapy followed by chemoradiotherapy in locally advanced pancreatic cancer:A literature review and report of two cases 165
An atlas for clinical target volume definition, including elective nodal irradiation in definitive radiotherapy of biliary cancer 165
null 164
Brain Metastases from Biliary Tract Cancer: A Monocentric Retrospective Analysis of 450 Patients 163
Fulminant hepatitis in a patient with hepatocellular carcinoma related to nonalcoholic steatohepatitis treated with sorafenib. 154
Combined low densities of FoxP3+ and CD3+ tumor-infiltrating lymphocytes identify stage II colorectal cancer at high risk of progression 154
Specific Toxicity of Maintenance Olaparib Versus Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis 154
Antitumoral Efficacy of Two Turmeric Extracts According to Different Extraction Methods in Hepatocellular Carcinoma Cell Lines 151
An astonishing case of liver-only metastatic colorectal cancer cured by FOLFOXIRI alone 151
Aspirin for cholangiocarcinoma prevention: New targets to shift the dogma from ascertained risk to possible prevention 149
Changes in the surgical approach to hilar cholangiocarcinoma during an 18-year period in a Western single center 149
Complete remission of primary colon cancer in a metastatic patient treated with CPT-11 plus capecitabine. 147
ACTIVATED NF-KB IN COLORECTAL CANCER: PREDICTIVE OR PROGNOSTIC FACTOR? 145
Genome-wide analysis identifies MEN1 and MAX mutations and a neuroendocrine-like molecular heterogeneity in Quadruple WT GIST 145
Cell proliferation and ultrastructural changes of the duodenal mucosa of patients affected by familial adenomatous polyposis. 142
SUSTAINED COMPLETE RESPONSE OF ADVANCED HEPATOCELLULAR CARCINOMA WITH METRONOMIC CAPECITABINE: A REPORT OF THREE CASES 142
null 142
HIV enteropathy: undescribed ultrastructural changes of duodenal mucosa and their regression after triple antiviral therapy. A case report 141
Can the tyrosine kinase inhibitors trigger metabolic encephalopathy in cirrhotic patients? 141
Clinical Target Volume in Biliary Carcinoma: A Systematic Review of Pathological Studies. 140
Membrane localization of human equilibrative nucleoside transporter 1 in tumor cells may predict response to adjuvant gemcitabine in resected cholangiocarcinoma patients 139
Membrane human equilibrative nucleoside transporter 1 is associated with a high proliferation rate and worse survival in resected intrahepatic cholangiocarcinoma patients not receiving adjuvant treatments 138
Cholangiocarcinoma: From risk to prevention? 137
Risk of duodenal adenomas in familial adenomatous polyposis to progress toward advanced neoplastic disease 136
Molecular imaging and targeted therapies in oncology: new concepts in treatment response assessment. a collection of cases. 135
Asbestos: a putative risk factor for intrahepatic cholangiocarcinoma 131
Whole exome sequencing (WES) on formalin-fixed, paraffin-embedded (FFPE) tumor tissue in gastrointestinal stromal tumors (GIST) 130
Venous thromboembolism and port-related thrombosis in metastatic colorectal cancer patients: a monocenter experience. 129
Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST) 129
Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: A proof of concept 129
Gene expression profiling of liver metastases from colorectal cancer as potential basis for treatment choice 128
Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene. 128
An exploratory study by DMET array identifies a germline signature associated with imatinib response in gastrointestinal stromal tumor 127
Surveillance for Hepatocellular Carcinoma Also Improves Survival of Incidentally Detected Intrahepatic Cholangiocarcinoma Arisen in Liver Cirrhosis 127
Molecular imaging suggests efficacy of bevacizumab beyond the second line in advanced colorectal cancer patients. 125
Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies 125
Breast carcinoma presenting as linitis plastica 123
Yttrium-90 radioembolization for unresectable/recurrent intrahepatic cholangiocarcinoma: a survival, efficacy and safety study 123
Bone metastases in biliary cancers: A multicenter retrospective survey 122
Occupational exposure to asbestos and risk of cholangiocarcinoma: a population-based case-control study in four Nordic countries 121
Dyskerin expression in human fetal, adult and neoplastic intrahepatic bile ducts: Correlations with cholangiocarcinoma aggressiveness 120
In Reply 118
Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: An analysis of the phase 3 REACH study 118
Treatment of colorectal cancer liver metastases 117
A multicenter survey on second-line chemotherapy for advanced biliary tract cancer 117
Effectiveness and cost-effectiveness of peri-operative versus post-operative chemotherapy for resectable colorectal liver metastases. 117
Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report 117
Genomic And Genetic Characterization of Cholangiocarcinoma Identifies Therapeutics Targets for Tyrosine Kinase Inhibitors 115
Intrahepatic cholangiocarcinoma: primary liver resection and aggressive multimodal treatment of recurrence significantly prolong survival. 112
Urease-Positive Bacteria Other than Helicobacter pylori in Human Gastric Juice and Mucosa 111
Re: Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations. 111
Efficacy of weekly docetaxel in locally advanced cardiac angiosarcoma 111
Estimation of the Survival Benefit Obtainable From Screening for the Early Detection of Pancreatic Cancer 111
Intestinal microflora and digestive toxicity of irinotecan in mice. 111
INTRAHEPATIC CHOLANGIOCARCINOMA DEVELOPMENT IN A PATIENT WITH A NOVEL BAP1 GERMLINE MUTATION AND LOW EXPOSURE TO ASBESTOS 111
Interactions between commensal bacteria and gut sensorimotor function in health and disease. 110
BIFIDOBACTERIACEAE IN THE ACHLORIDRIC STOMACH 110
Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation. 110
Postsorafenib systemic treatments for hepatocellular carcinoma: Questions and opportunities after the regorafenib trial 110
Second surgery or chemotherapy for relapse after radical resection of colorectal cancer metastases. 108
Capecitabine(CAP) based regimens vs infusional 5FU/AF in metastatic colorectal cancer cost/effectivness: the differences across the atlantic ocean 105
Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. 105
The role of metronomic capecitabine for treatment of recurrent hepatocellular carcinoma after liver transplantation 104
Impact of surgery on the development of duodenal cancer in patients with familial adenomatous polyposis. 103
Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements 103
Adjuvant Treatment and Follow-up Strategies 102
High prevalence of asbestos exposure in bile duct cancer patients 102
Bifidobacteria: microbiological aspects and probiotic potentialities 102
Irinotecan toxicity: genes or intestinal microflora? 101
Impact of adjuvant chemotherapy on time to relapse in cholangiocarcinoma. 101
Clinical safety and efficacy of adjuvant chemotherapy in radically resected cholangiocarcinoma patients. 101
Cholangiocarcinoma: Current opinion on clinical practice diagnostic and therapeutic algorithms. A review of the literature and a long-standing experience of a referral center 101
Plasma membrane localization of human equilibrative nucleoside transporter 1 (hENT-1) to predict better outcome of adjuvant gemcitabine in cholangiocarcinoma (CC) patients. 101
Heterotopic segmental liver transplantation on splenic vessels after splenectomy with delayed native hepatectomy after graft regeneration: A new technique to enhance liver transplantation 101
Cholangiocarcinoma: Epidemiology and risk factors 101
Metronomic capecitabine in advanced hepatocellular carcinoma patients:a phase II study. 100
Effect of the serine proteases inhibitor gabexate mesylate (GM) on the activity of gemcitabine (G) in cell lines of pancreatic cancer (PC) 100
Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? 99
Extrahepatic Feeding of HCC Limits the Use of TACE? Evidences from Literature and Clinical Experience 99
EXPOSURE TO ASBESTOS: A PUTATIVE UNKNOWN RISK FACTOR FOR INTRAHEPATIC CHOLANGIOCARCINOMA 99
Good performance of platinum-based chemotherapy for high-grade gastroenteropancreatic and unknown primary neuroendocrine neoplasms 99
KRAS and BRAF mutational status as selective criteria for targeted therapy in cholangiocarcinoma. 98
Durable Complete Response to Frontline Docetaxel in an Advanced Prostate Cancer Patient with Favourable CYP1B1 Isoforms: Suggestion for Changing Paradigms? 98
Radiotherapy or chemoradiation in unresectable biliary cancer: A retrospective study 98
Chemotherapy in Patients with Advanced Cholangiocarcinoma 97
Bifidobacteriaceae usually colonize human hypochloridric stomach 96
Radiotherapy in the management of gist: state of the art and new potential scenarios 96
EXOCRINE-ENDOCRINE PANCREATIC CANCER AND alpha-FETOPROTEIN 95
Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties. 95
Searching for novel multimodal treatments in oligometastatic pancreatic cancer 95
Totale 12.815
Salva come PNG Salva come JPEG
Categoria #
all - tutte 71.163
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 71.163
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.987 0 0 45 277 450 448 596 661 645 354 208 303
2020/20213.540 632 195 93 106 80 189 91 160 356 141 157 1.340
2021/20225.060 418 190 243 327 379 227 167 286 483 313 1.168 859
2022/20236.072 659 808 312 673 401 445 192 349 979 214 423 617
2023/20241.590 194 268 113 136 113 331 73 83 51 103 58 67
2024/20251.428 247 1.035 146 0 0 0 0 0 0 0 0 0
Totale 24.522